DEVELOPMENT OF ENZYMO-IMMUNOASSAYS (EIA) FOR MACROPHAGE COLONY-STIMULATING-FACTOR (M-CSF) AND LEUKAEMIA INHIBITORY FACTOR (LIF) BY USING THE SAME CAPTURE AND SIGNAL GENERATING POLYCLONAL ANTIBODY
详细信息 查看全文
文摘
Specific high titre polyclonal antibodies rapidly obtained by intralymphnode immunization of rabbits with recombinant M-CSF and LIF (<60 μg/animal) have been used to develop specific, accurate and sensitive EIAs. The same batch of purified anti-M-CSF or anti-LIF Igs has been used for the coating of 96—well plates (capture antibody) and for the quantitative detection of the bound cytokine molecules (soluble biotinylated Igs). The sensitivity (M-CSF: 10 IU/ml, LIF: 20 pg/ml), accuracy (intra-assay-CV: 8.2 to 12.8 % for M-CSF; 0 to 19.9 % for LIF) and reproducibility (inter-assay-CV: 7.9 to 13.6 % for M-CSF; 4.9 to 17.5 % for LIF) are equivalent to those for previously published RIAs or EIAs. These assays are highly specific since 11 other cytokines (Epo: 3 IU/ml; G-CSF: 100 IU/ml; CNTF, OSM, SCF, IL-1β, IL-2, IL-3, IL-6, IL-11, IL-13: 5 ng/ml) tested in both EIAs were not detectable. Finally, the M-CSF and LIF concentrations measured in various biological fluids were found to be similar to those measured by us and others with different assays. In conclusion, the methodology used for M-CSF and LIF EIAs presented in this work represents a valuable approach for most cytokines, particularly when they are still available in reduced amounts.